Management of Gastrointestinal Mucositis Due to Cancer Therapies in Pediatric Patients: Results of a Case Series with SAMITAL ®
- 14 November 2012
- journal article
- Published by Taylor & Francis in Future Oncology
- Vol. 8 (11) , 1481-1486
Abstract
Gastrointestinal mucositis is a common debilitating complication of chemotherapy and one for which there is currently no effective long-term treatment. To report our experience with the use of SAMITAL(®), a new oral suspension formulation based on the combination of three standardized extracts from Vaccinium myrtillus, Macleaya cordata fruits and Echinacea angustifolia roots in the prevention and treatment of chemotherapy-induced gastrointestinal mucositis in pediatric patients. 20 pediatric patients undergoing chemotherapy for a range of oncological conditions were followed. Patients initially received oral SAMITAL(®) to treat gastrointestinal mucositis and were then given SAMITAL(®) prophylactically to prevent recurrences with successive cycles of chemotherapy. SAMITAL(®) significantly decreased gastrointestinal mucositis grade after the first episode with a reduction of mean scores from 3.2 ± 0.7 at baseline to 0.4 ± 0.6 at the end of treatment (p < 0.001). SAMITAL(®) reduced pain, mucosal erosions, bleeding and dysphagia/feeding impairment. SAMITAL(®) improved patients' overall condition and quality of life after the first administration and lowered the need for parenteral nutrition. Importantly, it allowed chemotherapy cycles to be continued without complications. Results from this case series suggest that SAMITAL(®) may play an important role in the prevention and treatment of chemotherapy-induced gastrointestinal mucositis in children and adolescents and as such warrants investigation in controlled studies.Keywords
This publication has 16 references indexed in Scilit:
- Phytochemicals in the Oncology SettingCurrent Treatment Options in Oncology, 2010
- Management of oral and gastrointestinal mucositis: ESMO Clinical Practice GuidelinesAnnals of Oncology, 2010
- The development of evidence-based guidelines on mouth care for children, teenagers and young adults treated for cancerEuropean Journal of Cancer, 2010
- Abstract C245: Protein switches that activate a prodrug in the presence of HIF-1αMolecular Cancer Therapeutics, 2009
- Cannabinoid CB2receptors: a therapeutic target for the treatment of inflammatory and neuropathic painBritish Journal of Pharmacology, 2008
- Alkylamides from Echinacea Are a New Class of CannabinomimeticsJournal of Biological Chemistry, 2006
- The Endocannabinoid System as a Target for Alkamides fromEchinacea angustifoliaRootsPlanta Medica, 2005
- Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoeaThe Lancet Oncology, 2005
- Chemotherapy-Induced and/or Radiation Therapy-Induced Oral Mucositis-Complicating the Treatment of CancerNeoplasia, 2004
- Clinical and Microbiological Effects of a Sanguinaria‐Containing Mouthrinse and Dentifrice With and Without Fluoride During 6 Months of UseJournal of Periodontology, 1991